Kepala Batas

Researchers are evaluating elacestrant compared to standard endocrine therapies in adults with node-positive, Estrogen Receptor-positive ER, HER2-negative early breast cancer who are at high risk of cancer returning. The study focuses on those who have had prior endocrine therapy and aims to measure how well elacestrant may prevent invasive breast cancer recurrence over five years. Participants are randomly assigned to receive either 345 mg of elacestrant daily for five years or continue their prior standard endocrine therapy, which may include an aromatase inhibitor anastrozole, letrozole, or exemestane or tamoxifen. The trial is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will have regular assessments to monitor cancer recurrence, survival, side effects, and quality of life. Evaluations include questionnaires on health status and physical functioning at baseline, six months, and annually for up to five years. Safety is tracked through adverse event reporting up to five years plus 28 days. The total participation duration can last up to five years with ongoing monitoring and data collection.

Digital eye strain DES, also known as computer vision syndrome, includes various eye and vision problems caused by prolonged use of electronic devices such as computers, tablets, and cell phones. This issue affects many users, with symptoms related to eye focusing and dry eye conditions. The study aims to investigate whether astaxanthin, a natural antioxidant found in seafood and known for its potential eye health benefits, can help reduce DES symptoms, improve blue light-related complaints, and enhance cognitive function and quality of life in children aged 10 to 11 years who experience DES. The study compares two groups of children with DES one group will receive an oral astaxanthin supplement once daily for 24 weeks, while the other group will receive a placebo supplement containing olive oil once daily for the same period. This is a randomized, double-blind, placebo-controlled trial, meaning neither the participants, caregivers, nor researchers will know which treatment is given until the study ends. Participants will be involved for 24 weeks during which their symptoms will be assessed at the start, 12 weeks, and 24 weeks using a questionnaire specific to computer vision syndrome. Researchers will monitor changes in symptoms and gather information on eye strain, blue light effects, and overall quality of life. Safety and adherence to treatment will also be tracked throughout the study.